Cardiovascular diseasesTargeting innate immunity for CV benefit
Section editors:
Colin H. Macphee – Department of Vascular Biology, GlaxoSmithKline, King of Prussia, PA, USA
Alan Daugherty – Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA
Section snippets
Monocyte/macrophages
The macrophage, a major cellular effector of the innate immune response, is the predominant cell type in the early atherosclerotic lesion. This gives the macrophage a unique and primal role in the development and progression of atherosclerosis. Macrophages recognize and internalize modified lipoproteins leading to cellular cholesterol accumulation. Although initially beneficial, this protective response appears to become overwhelmed, leading to massive cellular cholesterol accumulation and the
Monocyte recruitment and innate immune targets
Central to the development of atherosclerotic lesions is the influx of monocytes into the arterial intima and the initiation of a chronic inflammatory milieu that drives plaque formation. Whereas monocyte recruitment is often cited as an early event in atherosclerosis, and therefore not considered an ideal target for the development of therapeutics in humans with established disease, it is very likely that monocyte ingress and egress are dynamic processes that actively contribute to lesion
Scavenger receptors
The conversion of subendothelial macrophages into cholesterol-laden foam cells is believed to constitute the foundation of the atherosclerotic lesion. Native LDL has traditionally not been considered capable of generating foam cells because cells downregulate their LDL receptor number with increasing cellular cholesterol content, precluding lipid loading via this pathway [9]. Modification of LDL is therefore required to drive lipid uptake by alternative receptor pathways. Over the past thirty
Scavenger receptor A
SRA was the first member of the scavenger receptor family to be molecularly identified and is expressed in monocytes/macrophages, smooth muscle and endothelial cells [17]. The role of SR-A in atherogenesis is currently controversial, as conflicting results have emerged from different groups studying the effect of targeted deletion and overexpression of SRA in multiple mouse models of atherosclerosis. Initial studies of SR-A deletion in the Apoe−/− mouse model on a hybrid background of ICR/129
CD36
CD36 is a member of the B class of the scavenger receptor family and unlike SRA, this receptor is widely expressed on monocytes/macrophages, adipocytes, microvascular endothelium, platelets, and erythroid precursors (reviewed in [12]). CD36 binds a diverse group of ligands that can contribute to atherosclerotic processes including endogenous ligands such as thrombospondin-1, collagen and fatty acids, as well as modified endogenous ligands such as oxidized LDL and apoptotic cells [12]. In
CXCL16/SR-PSOX
The scavenger receptor CXCL16, also known as SR-PSOX, is unique in that it combines scavenger receptor functions with the properties of an inflammatory chemokine (reviewed in [12]). Membrane bound CXCL16 is composed of a glycosylated mucin stalk fused to a chemokine domain that attracts cells expressing the receptor CXCR6 and also mediates the internalization of oxLDL, bacteria and apoptotic cells. The extracellular domain of CXCL16 also undergoes proteolytic cleavage generating a soluble
Toll-like receptors
Over the past decade the essential role of the Toll-like receptors in innate immune sensing of pathogens has become apparent (reviewed in [37]). This family of mammalian pattern recognition receptors has 11 members that act as homo- or hetero-dimers to recognize invariant patterns expressed on pathogens, including bacterial cell wall components and pathogen derived nucleotides. TLRs fall into two broad classes – the cell surface TLRs; TLR1/2/4/5/6 and the endosomal TLRs TLR3/7/8/9 (Fig. 2). The
Toll-like receptors as targets of inflammatory signaling pathways
Under normal conditions, endothelial cells express low levels of TLRs where these receptors perform innate immune surveillance. However, expression of TLR1, TLR2, TLR4 and TLR6 is markedly upregulated by endothelial cells and macrophages in atherosclerotic arteries suggesting a role for these TLRs in the initiation and/or maintenance of vascular inflammation [44]. Targeted deletion of MyD88, a key signaling adaptor for all TLRs except TLR3, provided the first genetic evidence of a role for
Therapeutic challenges in targeting innate immune pathways for atherosclerosis
Although the evidence implicating the activation of innate immunity pathways in atherosclerosis is strong, the challenges of creating new therapeutics directed at these pathways are formidable. The role of innate immunity in protecting against microbial pathogens raises the specter of rendering hosts susceptible to a multitude of infectious agents when these pathways are interrupted for therapeutic benefit. Many of the mice that have been genetically engineered to lack components of the innate
Conclusion
A growing body of basic science has implicated innate immunity pathways in the development and progression of atherosclerosis. These pathways result in the establishment of a sterile, chronic inflammation in the artery wall that ultimately leads to the narrowing of the arterial lumen and the subsequent rupture of plaques, which are the critical pathophysiological underpinnings of clinical coronary artery disease events. Our knowledge of the receptors involved in innate immunity and their
References (54)
- et al.
Regulation of the activity of the low density lipoprotein receptor in human fibroblasts
Cell
(1975) Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages
J. Biol. Chem.
(2002)Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice
Atherosclerosis
(1999)Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice
J. Lipid Res.
(2000)Macrophage-specific expression of class A scavenger receptors in LDL receptor(−/−) mice decreases atherosclerosis and changes spleen morphology
J. Lipid. Res.
(2002)Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knockout mice
Atherosclerosis
(2003)CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex
J. Biol. Chem.
(2007)Fibrillar amyloid protein present in atheroma activates CD36 signal transduction
J. Biol. Chem.
(2004)A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid
J. Biol. Chem.
(2002)Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36o /apoEo mice
Atherosclerosis
(2007)
Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein
J. Biol. Chem.
Macrophage foam cell formation with native low density lipoprotein
J. Biol. Chem.
The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis
Am. J. Pathol.
Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells
J. Biol. Chem.
Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein
J. Biol. Chem.
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Lancet
Atherosclerosis – an inflammatory disease
N. Engl. J. Med.
Atherosclerosis
Nature
The immune response in atherosclerosis: a double-edged sword
Nat. Rev. Immunol.
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata
J. Clin. Invest.
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques
J. Clin. Invest.
Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice
Circulation
New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice
Circulation
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice
Circ. Res.
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
N. Engl. J. Med.
Role of oxidative modifications in atherosclerosis
Physiol. Rev.
Scavenger receptors in atherosclerosis: beyond lipid uptake
Arterioscler. Thromb. Vasc. Biol.
Cited by (4)
Stigmasterol inhibits lipopolysaccharide-induced innate immune responses in murine models
2017, International ImmunopharmacologyCitation Excerpt :The role of the innate immune system previously viewed as merely a non-specific, first-line defense mechanism has evolved over the years. Studies have shown a more critical and specialized role in disease pathogenesis [8–10]. Hyperactivity and imbalance in the immune system accounts for the underlying pathophysiology of several conditions such as rheumatoid arthritis, hypersensitivity reactions and septic shock [11,12].
Targeting mast cells: Uncovering prolific therapeutic role in myriad diseases
2016, International ImmunopharmacologyCitation Excerpt :They are proteins expressed by cells of the innate immune system and recognize pathogen associated molecular patterns (PAMPs). Pattern recognition receptors include Toll-like receptors (TLRs), nod-like receptors (NLRs), and retinoic acid inducible gene 1 (RIG-1)-like receptors (RLRs) [47–50]. Binding of immunoglobulin E to FcεRI, result in activation of mast cells by involving cascade of events, thereby lead to release of inflammatory mediators.